Skip to main content

Septerna, Inc.

corporate_fare Company Profile

Septerna, Inc.

SEPN·NASDAQ·Life Sciences·CIK 0001984086

Septerna, Inc. is a clinical-stage biotechnology company focused on discovering oral small molecule drugs targeting G protein-coupled receptors (GPCRs). The company utilizes its proprietary Native Complex Platform® to achieve this. This industrial-scale platform aims to develop GPCR therapies and has resulted in a pipeline of product candidates. Initially, these candidates are focused on treating patients in three therapeutic areas: endocrinology, immunology and inflammation, and metabolic diseases. GPCRs are the largest and most diverse family of cell membrane receptors, regulating physiological processes throughout the human body. They represent the most productive target class in drug discovery history, accounting for approximately one-third of all FDA-approved drugs. In 2023, these drugs generated combined global revenue of approximately $125 billion. Despite this success, about 75% of potential GPCR therapeutic targets remain undrugged. The Native Complex Platform® replicates the natural structure, function, and dynamics of GPCRs outside of cells at an industrial scale. This technology allows Septerna to isolate, purify, and reconstitute full-length, properly folded GPCR proteins within ternary complexes, including ligands and transducer proteins, in a lipid bilayer that mimics the cell membrane. The company then applies discovery tools and technologies to these protein complexes to design, screen for, and optimize potential product candidates.

Septerna, Inc. (NASDAQ:SEPN) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 16 items for SEPN at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-09, rated 7/10. Across its 16 most recent items scored 7 or higher, the top rating is 9/10, with 5 rated 8 or above. Recent SEC coverage for SEPN spans 10-Q, 8-K, SCHEDULE 13D/A, 144.

Recent high-impact activity:

  • Septerna 10-Q: Q3 Revenue $18.9M, Net Loss $26.6M, $565.2M Cash Into Mid-2029
  • Septerna Posts $18.9M in Third-Quarter Revenue
  • Septerna Names SEP-204 Development Candidate for Graves' Disease and TED; Phase 1 Set for Q1 2027
  • RA Capital Sells 1.49M Septerna Shares at $42.50 in Block Trades
  • RA Capital Files to Sell $36M of Septerna Shares

Financial Snapshot

Fiscal year ended December 31, 2025
Revenue
$45.95M
Net Income
-$48.88M
Diluted EPS
-$1.10
Op. Cash Flow
$110.19M
Free Cash Flow
$109.67M
Operating Income
-$68.3M
Cash & Equivalents
$120.72M
Debt / Equity
0.00×
Net Margin
-106.4%
Shares Outstanding
44.81M sh
Source: 10-K · filed 2026-03-09 · accession 0001193125-26-098507

Short Interest & Short Volume

11.95 days to cover

FINRA reported short interest of 3,352,395 shares in SEPN as of the October 30, 2026 settlement, a 4.8% decrease from the prior period — about 11.9 days to cover at its recent average daily volume. On November 19, 2026, 72.6% of SEPN volume reported to FINRA trade-reporting facilities was marked short.

Short interest (bi-monthly positions)3,352,395 shares as of October 30, 2026
Change vs prior period▼ 4.8%
Days to cover11.95 at avg daily volume of 280,562
Daily short volume (FINRA facilities)72.6% of 77,579 shares on November 19, 2026
5-day average short volume67.4%

Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.

Browse all tickers starting with S →
$38.61
52-week range · as of 2026-11-09 $17.55 – $51.1
Market cap
$1.84B
Volume
374.2K (1.0× avg)
3-mo avg 388.6K
Live data · 2026-11-20 22:45 UTC · After hours

show_chartPrice Chart

Loading chart...

feed SEPN - Latest Insights

SEPN
Nov 09, 2026, 4:06 PM EST
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $50.74
Real-time Price: $38.61 info
Change: -$12.13 (-24%) info
Market Cap: $1.836B info
SEPN
Nov 09, 2026, 4:03 PM EST
Source: Dow Jones Newswires
Importance Score:
7
Price at Filing: $50.74
Real-time Price: $38.61 info
Change: -$12.13 (-24%) info
Market Cap: $1.836B info
SEPN
Nov 04, 2026, 8:15 AM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $43.70
Real-time Price: $38.61 info
Change: -$5.09 (-12%) info
Market Cap: $1.836B info
SEPN
Aug 14, 2026, 5:14 PM EDT
Filing Type: SCHEDULE 13D/A
Importance Score:
7
Price at Filing: $45.39
Real-time Price: $38.61 info
Change: -$6.78 (-15%) info
Market Cap: $1.836B info
SEPN
Aug 12, 2026, 6:55 PM EDT
Filing Type: 144
Importance Score:
7
Price at Filing: $48.19
Real-time Price: $38.61 info
Change: -$9.58 (-20%) info
Market Cap: $1.836B info
SEPN
Jun 22, 2026, 4:16 PM EDT
Filing Type: 144
Importance Score:
7
Price at Filing: $34.85
Real-time Price: $38.61 info
Change: +$3.76 (+11%) info
Market Cap: $1.836B info
SEPN
May 11, 2026, 4:08 PM EDT
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $23.57
Real-time Price: $38.61 info
Change: +$15.04 (+64%) info
Market Cap: $1.836B info
SEPN
May 11, 2026, 4:05 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $23.57
Real-time Price: $38.61 info
Change: +$15.04 (+64%) info
Market Cap: $1.836B info
SEPN
Apr 13, 2026, 8:30 AM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $23.09
Real-time Price: $38.61 info
Change: +$15.52 (+67%) info
Market Cap: $1.836B info
SEPN
Apr 13, 2026, 8:00 AM EDT
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $23.09
Real-time Price: $38.61 info
Change: +$15.52 (+67%) info
Market Cap: $1.836B info
SEPN
Mar 10, 2026, 4:31 PM EDT
Filing Type: S-3ASR
Importance Score:
7
Price at Filing: $28.02
Real-time Price: $38.61 info
Change: +$10.59 (+38%) info
Market Cap: $1.836B info
SEPN
Mar 09, 2026, 4:22 PM EDT
Source: Reuters
Importance Score:
9
Price at Filing: $29.06
Real-time Price: $38.61 info
Change: +$9.55 (+33%) info
Market Cap: $1.836B info
SEPN
Mar 09, 2026, 4:11 PM EDT
Filing Type: 10-K
Importance Score:
7
Price at Filing: $29.06
Real-time Price: $38.61 info
Change: +$9.55 (+33%) info
Market Cap: $1.836B info
SEPN
Mar 02, 2026, 7:00 AM EST
Filing Type: 8-K
Importance Score:
8
Price at Filing: $28.40
Real-time Price: $38.61 info
Change: +$10.21 (+36%) info
Market Cap: $1.836B info
SEPN
Mar 01, 2026, 9:47 AM EST
Source: Reuters
Importance Score:
8
Price at Filing: $29.02
Real-time Price: $38.61 info
Change: +$9.59 (+33%) info
Market Cap: $1.836B info
SEPN
Jan 12, 2026, 8:30 AM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $25.30
Real-time Price: $38.61 info
Change: +$13.31 (+53%) info
Market Cap: $1.836B info
Research tools: Filing Impact Index Dilution Tracker Split Calendar Open Datasets